Quantcast

Latest Cetuximab Stories

993b7fa2eb16189ed4c0f49d15b0f0dc1
2009-06-30 13:32:10

Two experts from the National Institutes of Health have released a new report which questions the use of expensive treatments for cancer patients that only extend their lifespan for a short time. In comments published in the Journal of the National Cancer Institute, Tito Fojo, of the Medical Oncology Branch, Center of Cancer Research at the National Cancer Institute, in Bethesda, Maryland, and Christine Grady, of the Department of Bioethics, the Clinical Center at the National Institutes of...

2009-06-29 15:46:37

The decision to use expensive cancer therapies that typically produce only a relatively short extension of survival is a serious ethical dilemma in the U.S. that needs to be addressed by the oncology community, according to a commentary published online June 29 in the Journal of the National Cancer Institute.Tito Fojo, M.D., Ph.D., of the Medical Oncology Branch, Center of Cancer Research at the National Cancer Institute, in Bethesda, Md., and Christine Grady, Ph.D., of the Department of...

2009-06-01 13:30:00

New Merck KGaA Study Reveals Wide Variations in Therapy Regimens, with Monotherapy Most Common in Elderly Patients and Triplets Most Prevalent in the US ORLANDO, Fla., June 1 /PRNewswire/ -- There are striking differences in treatment regimens for non-small cell lung cancer (NSCLC) patients, based on both age and geography, according to a new market research study conducted by Merck KGaA, Darmstadt, Germany, presented as a poster on Saturday at the 2009 ASCO (American Society of Clinical...

2009-06-01 08:06:00

Data Presented Today at American Society of Clinical Oncology ORLANDO, Fla., June 1 /PRNewswire/ -- Precision Therapeutics, Inc. today presented data demonstrating the use of ChemoFX(R), a chemosensitivity assay, to predict the effectiveness of cetuximab (ERBITUX(R)) on the colorectal cancer cells of individual patients. Results from the study show that of the 54 primary colorectal cultures tested, eight percent were responsive to cetuximab, a result that is consistent with the reported...

2009-06-01 07:30:00

KRX-0401 + Capecitabine More Than Doubles Time to Progression and Overall Response Rate as well as Extends Overall Survival vs. Capecitabine + Placebo in Patients with 2nd or 3rd Line Metastatic Colon Cancer NEW YORK, June 1 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) yesterday announced data on the clinical activity of KRX-0401 (perifosine), the Company's Akt-inhibitor for cancer, in combination with capecitabine as a treatment for advanced colon cancer....

2009-06-01 07:09:00

- Results from a randomized Phase IIb trial reported at 2009 ASCO Annual Meeting - MISSISSAUGA, ON, June 1 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported that results from a randomized trial of nimotuzumab (aka BIOMAb/TheraCIM/h-R3) in patients with inoperable,...

2009-05-31 07:30:00

KRX-0401 + Capecitabine More Than Doubled Time to Progression and Overall Response Rate as well as Extended Overall Survival vs. Capecitabine + Placebo in Patients with 2nd or 3rd Line Metastatic Colon Cancer NEW YORK, May 31 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced data on the clinical activity of KRX-0401 (perifosine), the Company's Akt-inhibitor for cancer, in combination with capecitabine as a treatment for advanced colon cancer. Abstract...

2009-05-29 13:36:33

The vast majority of advanced colon cancer patients in a clinical trial were not concerned about the cost of prescription drugs for managing chemotherapy side effects, such as infection, pain and nausea and few adopted strategies to reduce drug cost burdens after joining the clinical trial, according to a study led by researchers at Dana-Farber Cancer Institute in Boston. Although few patients reported substantial worry about drug costs, still fewer reported discussing drug cost issues with...

2009-05-27 08:13:49

Novel chemotherapy and biological agents for metastatic colorectal cancer, combined with surgical advances in liver resection, have resulted in a dramatic increase in survival for patients with advanced disease, according to researchers at The University of Texas M. D. Anderson Cancer Center.Published in the Journal of Clinical Oncology, it is the first study in the last 20 years to examine the survival rates for metastatic colorectal cancer, and finds that the median overall survival is now...

2009-05-15 08:29:00

New Vectibix(R) (Panitumumab) Combination Chemotherapy Data New Data Reinforce Importance of Infection Prevention in Chemotherapy Patients Oncology Pipeline Continues to Advance With New Data in Multiple Tumor Types THOUSAND OAKS, Calif., May 15 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced it will present new data from the Company's oncology portfolio of approved and investigational cancer products at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting...


Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related